Belite Bio, Inc (BLTE): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLTE Stock Price Chart Interactive Chart >
BLTE Price/Volume Stats
|Current price||$30.26||52-week high||$44.70|
|Prev. close||$29.98||52-week low||$8.80|
|Day high||$30.42||Avg. volume||6,708|
|50-day MA||$30.34||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||752.48M|
Belite Bio, Inc (BLTE) Company Bio
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Most Popular Stories View All
BLTE Latest News Stream
|Loading, please wait...|
BLTE Latest Social Stream
View Full BLTE Social Stream
Latest BLTE News From Around the Web
Below are the latest news stories about BELITE BIO INC that investors may wish to consider to help them evaluate BLTE as an investment opportunity.
If so, you should know that investors like you found what they were looking for this year in the biotechnology and medical technology spaces. Shares of Belite Bio (NASDAQ: BLTE) are up about 209% this year. Investors have been piling into this clinical-stage biotechnology company thanks to encouraging early results from its lead candidate, LBS-008.
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE - Research Report), with a price target of $58.00. The company's shares opened today at $27.50.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -29.6% and a 22.28% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Belite Bio, Inc. ADR with a $58.00 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $44.
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)There are currently no approved treatments for STGD1 and Dry AMDCurrently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1 patients (the “DRAGON” study) is recruiting subjects12-month interim data from t
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27th at 11 AM ET SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, will host a key opinion leader (KOL) event with a focus on LBS-008 (aka Tinlarebant), the Company’s lead asset for the treatment of Stargardt Disease
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE - Research Report), with a price target of $58.00. The company's shares closed last Friday at $33.55.Chen covers the Healthcare sector, focusing on stocks such as Veru, Belite Bio, Inc. ADR, and Applied DNA Sciences. According to TipRanks, Chen has an average return of -22.4% and a 26.30% success rate on recommended stocks. Belite Bio, Inc. ADR has an analyst consensus of Moderate Buy, with a price target consensus of $57.50.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $44.70 and a one-year low of $8.80.
BLTE Price Returns